Clinical Trial

Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With Cirrhosis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Muscle cramps are common in patients with liver disease and associated with significantly diminished quality of life. Patients with cirrhosis often experience muscle cramps with varied frequency and severity. The exact mechanisms by which they occur remain unclear, although a number of pathophysiological events unique to liver disease may contribute. Clinical studies have identified alterations in 3 areas: nerve function, energy metabolism, and plasma volume/electrolytes (1) Orphenadrine is an anticholinergic drug with prominent central nervous system (CNS) and peripheral actions used to treat painful muscle spasms and other similar conditions. The combination of anticholinergic effects and CNS penetration make orphenadrine useful for pain of all etiologies, including from: radiculopathy, muscles, and headaches. \[3,4\]
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2015-04-21; most recent amendment 2019-06-06.
Trial Details
NCT Number NCT02423395
Lead Sponsor Sherief Abd-Elsalam
Collaborators: Tanta University
Conditions Liver Cirrhosis, Muscle Cramps
Enrollment 100 participants
Start Date 2015-01
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2019-06-07